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In Brief Sullivan-Reed et al. show that simultaneous treatment with PARP and RAD52 inhibitors exerts dual synthetic lethality in BRCA-deficient tumors. Addition of RAD52 inhibitor should improve therapeutic outcome of BRCAdeficient malignancies treated with PARP inhibitor.
INTRODUCTION
Numerous reports indicate that tumor cells accumulate high levels of spontaneous and drug-induced DNA damage, but they survive because of enhanced or altered DNA repair activities (Bartkova et al., 2005) . PARP1 may prevent accumulation of potentially lethal DNA double-strand breaks (DSBs) by playing a key role in base excision repair (BER), single-strand break (SSB) repair, and alternative non-homologous endjoining (Alt-NHEJ) and/or by facilitating MRE11-mediated recruitment of RAD51 to promote stalled replication fork restart (Metzger et al., 2013; Ying et al., 2012) . Homologous recombination (HR), which depends mostly on BRCA1-PALB2-BRCA2-RAD51 paralogs-RAD51-RAD54 (BRCA-HR), and RAD52-dependent single-strand annealing (RAD52-SSA) play an important role in DSB repair in proliferating cells (Kass and Jasin, 2010) .
The hypothesis that cancer cells are addicted to particular DNA repair pathways is supported by selective targeting of tumor cells by recently developed novel drugs and compounds against specific DNA repair mechanisms (Nickoloff et al., 2017) . The success of the PARP inhibitor (PARPi) olaparib in BRCA1-and BRCA2-deficient breast tumors has established a proof of concept of personalized cancer therapy using synthetic lethality (Lord et al., 2015) . Unfortunately, therapeutic effect is usually short-lived, and tumor cells become unresponsive to PARPi because of compensatory mechanisms such as restoration of HR via secondary mutations in BRCA2, PALB2, RAD51 paralogs (RAD51C, RAD51D), or loss of 53BP1, impaired drug uptake, and/or enhanced drug efflux . In concordance, we showed that BRCA-deficient breast carcinoma cells and leukemia cells could not be completely eradicated by PARPi (Nieborowska-Skorska et al., 2017) . Therefore, more robust and rapid elimination of BRCA-deficient tumor cells is required to prevent time-dependent emergence of PARPi-resistant or refractory clones.
It has been suggested that RAD52-dependent HR pathways involving RAD51 (RAD52-HR) and/or RAD52-SSA can act as backups to the main BRCA-mediated HR pathway (BRCA-HR) (Stark et al., 2004; Wray et al., 2008) . We hypothesized that RAD52-HR and/or RAD52-SSA represent potential escape route(s) from PARPi-mediated synthetic lethality in BRCA-deficient cells and that simultaneous inhibition of PARP and RAD52-dependent DNA repair pathways would trigger more effective ''dual'' synthetic lethality.
RESULTS

Inhibition of RAD52 Attenuated Residual HR Activity in
PARPi-Treated BRCA-Deficient Tumor Cell Lines BRCA1/2-deficient and BRCA1/2-proficient cells carrying DR-GFP recombination reporter cassette were co-transfected with pCBASceI (encoding I-Sce1 endonuclease generating a DSB in the reporter cassette) and pDsRed (transfection efficiency control) expression plasmids. As expected, BRCA1 and BRCA2 deficiencies were associated with reduced HR measured by the percentage of GFP+ cells in DsRed+ population, but residual HR activity was consistently detectable in BRCA-deficient cells (Figures 1A and 1B) . PARPis olaparib and talazoparib did not affect HR activities in BRCA-deficient and proficient cells. However, a previously described RAD52i, 6-hydroxy-DL-dopa (Dopa) , abrogated residual HR activity in naive and PARPi-treated BRCA-deficient cells without affecting BRCA-proficient counterparts.
In addition, RAD51 foci could be applied as a surrogate marker for HR activity (Oplustilova et al., 2012) . We employed BRCA1-deficient HCC1937 cells, in which RAD51 foci formation depends on RAD52 (Lok et al., 2013) . We detected that RAD52i wild-type clone 92B cells (BRCA1+) (B) carrying DR-GFP cassette were co-transfected with I-SceI and DsRed cDNAs, followed by treatment with 5 mM olaparib (Ola), 50 nM talazoparib (Tala), and/or 10 mM 6-OH-dopa (Dopa), or were left untreated (Control). Results represent mean percentage of GFP+DsRed+ cells in DsRed+ population ± SD from three independent experiments; *p < 0.05 in comparison with untreated control. (C) BRCA1-mutated HCC1937 cells (BRCA1À) and HCC1937 expressing wild-type BRCA1 (BRCA1+) were treated with 3 mg/mL cisplatin (Control) and cisplatin combined with 5 mM olaparib (Ola) and/or 10 mM 6-OH-dopa (Dopa). Results represent percentage of cells with more than ten RAD51 foci from three independent experiments (100 cells/experiment were evaluated); *p < 0.05 in comparison with untreated control. (D) BRCA2À/À murine ES clone 42E cells (BRCA2À) and BRCA2 wild-type clone 40b cells (BRCA2+) carrying SA-GFP cassette were co-transfected with I-SceI and DsRed cDNAs, followed by treatment with 1.25 mM olaparib (Ola) and/or 20 mM 6-OH-dopa (Dopa), or were left untreated (Control). Results represent mean percentage of GFP+DsRed+ cells in DsRed+ population ± SD from three independent experiments; *p < 0.05 in comparison with untreated control. See also Figure S1 . Dopa, but not PARPi olaparib, inhibited cisplatin-induced RAD51 foci formation in BRCA1-deficient HCC1937 cells but not in BRCA1-proficient counterparts ( Figure 1C ). Moreover, Dopa reduced RAD51 foci formation in olaparib-treated BRCA1-deficient HCC1937 cells. As expected, RAD52i Dopa inhibited SSA activity in BRCA2-deficient and BRCA2-proficient cells and also in olaparib-treated cells ( Figure 1D ).
The importance of RAD52 was further supported by significantly higher relapse-free survival probability of the patients with leukemias displaying low expression levels of one of the BRCA-HR gene (BRCA1, BRCA2, PALB2, RAD51) and RAD52 gene compared with those with leukemias expressing high levels of these genes ( Figure S1 ). In concordance, RAD52i reduced HR and SSA activities in BRCA-deficient tumor cells when applied alone or in combination with PARPi, suggesting that RAD52 promotes survival of PARPi-treated BRCA-deficient cells. This observation provided justification for the investigation of the potency of dual synthetic lethal effect exerted by simultaneous targeting of PARP and RAD52 in BRCA-deficient tumor cells.
RAD52i Enhanced the Synthetic Lethal Effect of PARPi, Causing Complete Eradication of BRCA-Deficient Tumor Cells In Vitro
Simultaneous treatment of BRCA1-deficient MDA-MB-436 tumor cells with PARPi olaparib and RAD52i Dopa resulted in enhanced accumulation of DSBs detected by neutral comet assay and g-H2AX immunofluorescence and synergistic inhibition of cell growth in comparison with treatment with individual inhibitors, while BRCA-proficient counterparts were not affected by these inhibitors (Figure 2A ). Similar growth inhibitory effect in BRCA1-deficient MDA-MB-436 cells was exerted by olaparib combined with RAD52i D-I03 (Huang et al., 2016) (Figure 2B ). Moreover, combination of PARPi olaparib and RAD52i F79 aptamer (Cramer-Morales et al., 2013) synergistically inhibited the growth of BRCA1-deficient UWB1.289, MDA-MB-436, and HCC1937 tumor cell lines and BRCA2-deficient Capan-1 tumor cells compared with individual treatments ( Figure 2C ). BRCA-proficient counterparts and nontransformed NIH 3T3 cells were not affected by the inhibitors. PARPi and RAD52i did not cause downregulation of PARP1 and RAD52 proteins implicating functional inhibition of the targeted proteins ( Figure S2A) .
Hence, these data show consistent and selective killing of BRCA-deficient cells by dual treatment with PARPi (i.e., olaparib, talazoparib) and one of three different RAD52i (i.e., F79 aptamer, Dopa, D-I03), which validates RAD52 as an attractive target for inhibition along with PARPi.
The effect of dual synthetic lethality may be triggered selectively in BRCA-deficient cells. MLL-AF9-positive leukemia cells are BRCA proficient, but they are sensitive to PARPi, especially when combined with standard cytotoxic drug (Maifrede et al., 2017b) . However, these cells did not respond favorably to the combination of PARPi + RAD52i ( Figure S2B ), most likely because PARP1-dependent but not RAD52-mediated mechanisms play a major role in their DNA repair.
Importantly, long-term continuous treatment (28 days) with PARPi (olaparib) + RAD52i (Dopa) led to eradication of BRCA1-and BRCA2-deficient cells, while individual agents generated partial inhibition of the growth rate ( Figure 2D ). At the end of 28 days of continuous treatment, double-treated cells were washed out of the drugs and incubated in drug-free medium. Remarkably, no living cells were retrieved even after 14 days of culture.
We also examined the effect of combination treatment on leukemia cells deficient in another BRCA-HR gene, RAD54 (Mazin et al., 2010) . Simultaneous short-term treatment of RAD54À/À Nalm-6 human leukemia cell line but not RAD54+/+ parental cells with PARPi olaparib and RAD52i Dopa enhanced accumulation of DSBs assessed by neutral comet assay and g-H2AX immunofluorescence and eliminated significantly more cells, as determined by trypan blue exclusion test, compared with individual drugs (Figures S2C-S2E) . Moreover, long-term (35 days) combinatorial treatment resulted in complete elimination of RAD54À/À Nalm-6 cells, whereas individual inhibitors exerted only partial effect ( Figure S2F ). At the end of the experiment, living RAD54À/À Nalm-6 cells were not detected after a 14 day incubation of double-treated cells in drug-free medium.
In addition, a combination of olaparib and Dopa exerted a much stronger inhibitory effect against BRCA2-deficient Burkitt lymphoma (BL)-derived Epstein-Barr virus (EBV)-positive B cell lines Mutu and Raji ) compared with individual inhibitor treatment ( Figure S2G ). At the same time, BRCA2-proficient EBV-immortalized lymphoblastoid cell lines (LCL1 and LCL2) established from healthy donor cells were not sensitive to these inhibitors.
To rule out possible off-target effects of the small-molecule inhibitors, dominant-negative mutants of PARP1 and RAD52 were used. Ectopic expression of catalytically inactive PARP1(E988K) mutant downregulated protein PARylation and expression of DNA binding-defective RAD52(F79A) mutant reduced RAD52 foci formation ( Figure S3 ). PARP1(E988K) and RAD52(F79A) when expressed individually were able to selectively inhibit the growth of BRCA1-deficient MDA-MB-436 cells and BRCA2-deficient EUFA423 cells ( Figure 2E ). Importantly, co-expression of PARP1(E988K) and RAD52(F79A) mutants exerted synergistic growth inhibitory effect in MDA-MB-436 cells and EUFA423 cells, whereas BRCA1/2-reconstituted counterparts were not affected.
In conclusion, our data show that simultaneous targeting of PARP1 and RAD52 by small-molecule inhibitors or dominantnegative mutants facilitates accumulation of toxic DSBs, resulting in selective elimination of tumor cells displaying deficiencies in BRCA-mediated HR. Moreover, prolonged combinatorial treatment completely eradicated BRCA-deficient cells, demonstrating a highly robust method for selective killing of these cells.
Combination of PARPi and RAD52i Eliminated BRCADeficient Primary Leukemia Cells More Efficiently Than Individual Inhibitors We and others reported previously that several oncogenes, such as BCR-ABL1, AML1-ETO, and IGH-MYC, but not FLT3(ITD) and MLL-AF9, inhibit BRCA1/2 protein expression, resulting in synthetic lethality triggered by PARP and/or RAD52 inhibitors used individually (Cramer-Morales et al., 2013; Fan et al., 2010; Maifrede et al., 2017a; Nieborowska-Skorska et al., 2017; Podszywalow-Bartnicka et al., 2014 ). Here we tested the effect of (C) Indicated BRCA1/2-deficient cells and BRCA1/2-reconstituted counterparts were treated with 1mM olaparib (Ola) and/or 1mM F79 aptamer (F79) added at 0 and 2 days, followed by trypan blue counting at day 5. Mean percentage of viable cells ± SD relative to untreated counterparts (three experiments). *p < 0.04 in comparison with cells treated with individual drugs using the response additivity approach. (D) Indicated BRCA1/2-deficient cells were left untreated (black) or continuously treated with 2.5 mM olaparib (blue), 20 mM Dopa (green), and olaparib+Dopa (red) for 28 days. Results represent mean cumulative number of viable cells ± SD (triplicate experiments). (E) BRCA1-deficient and BRCA1 reconstituted MBA-MB-436 cells and BRCA2-deficient and BRCA2 reconstituted EUFA423 cells were transfected with PARP1 and/or RAD52 wild-type or PARP1(E988K) and/or RAD52(F79A) dominant-negative mutants. Results represent relative growth of the cells expressing dominantnegative mutant(s) relative to these expressing wild-type proteins from at least three experiments. *p < 0.02 compared with BRCA1/2-proficient counterparts using Student's t test; **p % 0.01 compared with BRCA1/2-deficient cells transfected with individual mutants using the response additivity approach. See also Figures S2 and S3. combination PARPi+RAD52i treatment on BRCA1/2-deficient and BRCA1/2-proficient patient leukemia cells. Three different RAD52is and two PARPis were applied to exclude the possibility that the effect depends on non-specific properties of an individual inhibitor.
Combination of sub-optimal concentrations of olaparib and Dopa exerted a strong effect against primary BRCA1/2-deficient leukemia and lymphoma cells expressing BCR-ABL1, AML1-ETO, or IGH-MYC but not against BRCA1/2-proficient normal cells and leukemia cells expressing FLT3(ITD) ( Figure 3A) . Moreover, long-term continuous treatment (28 days) of the cells from very aggressive BCR-ABL1-positive CML-blast phase (CML-BP) with PARPi (olaparib) + RAD52i (Dopa) led to eradication of leukemia cells, while individual agents generated only partial inhibition ( Figure 3B ). At the end of 28 days of continuous treatment, double-treated cells were washed out of the drugs and incubated in drug-free medium. Remarkably, no living cells were retrieved even after 14 days of culture. In addition, CML-BP cells were sensitive to the combination of sub-optimal concentrations PARPi talazoparib + RAD52i D-I03, and addition of imatinib (BCR-ABL1 kinase inhibitor) to talazoparib + D-I03 resulted in complete eradication of clonogenic cells ( Figure 3C ).
Using DR-GFP recombination reporter cassette and/or BRCA1/2 expression and foci formation, we were able to identify several BRCA-deficient and BRCA-proficient samples from individual acute myeloid leukemia (AML) and therapy-related myelodysplastic syndrome (t-MDS) patients (Cramer-Morales et al., 2013; Nieborowska-Skorska et al., 2017) . These cells were treated with sub-optimal concentrations of the cytotoxic drug daunorubicin (DNR), PARPi olaparib, and/or RAD52i F79 aptamer. The combination of olaparib + F79 aptamer exerted much stronger inhibitory effect than individual compounds (D) BRCA pathway-deficient and BRCA pathway-proficient AML (n = 3 of each) were treated with 0.125 mg/mL daunorubicin (DNR), 1.25 mM olaparib, and/or 1.25 mM F79. (E) BRCA pathway-deficient and BRCA pathway-proficient t-MDS/AML (n = 3 of each) were treated with 1.25 mM olaparib and/or 1.25 mM F79. Cells were treated at 0 and 48 hr, followed by counting in trypan blue (B) or plating in methylcellulose at 96 hr (D); colonies were counted after 7-10 days (A, C, and E). Results represent mean percentage ± SD of surviving colonies/cells. *p < 0.05 in comparison with single and dual treatments, respectively, using Student's t test; **p = 0.02 compared with DNR+Ola, DNR+F79, Ola, and F79 using the response additivity approach.
against AML cells from BRCA-deficient but not BRCA-proficient patients ( Figures 3D and 3E ). Triple combination of DNR + olaparib + F79 aptamer exerted synergistic effect compared with dual combinations of these compounds ( Figure 3D ).
In conclusion, combination of PARPi+RAD52i exerted stronger inhibitory effect than individual inhibitors specifically in BRCA-deficient leukemia and lymphoma cells. Addition of standard therapeutic drug (e.g., imatinib for CML-BP and DNR for AML) enhanced the effect of PARPi+RAD52i, suggesting a potentially beneficial therapeutic application of this approach.
Simultaneous Targeting of PARP1 and RAD52 Exerted a Synergistic Effect against BRCA-Deficient Tumors in Mice BCR-ABL1 oncogenic tyrosine kinase induces translational repression and degradation of BRCA1 protein, which makes leukemia cells sensitive to PARPi and RAD52i (Cramer-Morales et al., 2013; Dkhissi et al., 2015; Nieborowska-Skorska et al., 2017; Podszywalow-Bartnicka et al., 2014) . To study the effect of PARPi+RAD52i against BRCA1-deficient BCR-ABL1-positive leukemias, we employed a tet-off SCLtTA/p210BCR-ABL1 transgenic mouse model, which upon withdrawal of tetracycline develops CML-CP-like disease (Koschmieder et al., 2005) . Bone marrow cells from SCLtTA/p210BCR-ABL1 transgenic mice cultured in the absence of tetracycline were sensitive to PARPi olaparib and RAD52i Dopa, but the combination of these two inhibitors exerted a synergistic anti-leukemia effect ( Figure 4A ). As expected, BCR-ABL1 protein was expressed and BRCA1 protein was downregulated in the absence of tetracycline ( Figure 4B) .
To test the effect of PARP1 and RAD52 inhibition on BRCA1-deficient BCR-ABL1 leukemia in genetic settings, we generated Parp1À/À;Rad52À/À mice, which did not display any detectable defects in various inspected organs, including bone marrow ( Figures S4A-S4D ). Next, we obtained SCLtTA/p210BCR-ABL1/ Parp1À/ÀRad52À/À, SCLtTA/p210BCR-ABL1/Parp1À/À, SCLtTA/p210BCR-ABL1/Rad52À/À, and SCLtTA/p210BCR-ABL1 mice. Bone marrow cells from these mice cultured in the absence of tetracycline expressed BCR-ABL1 kinase and displayed downregulation of BRCA1 protein ( Figure 4B ).
BCR-ABL1-mediated clonogenic potential was calculated as the difference between the numbers of colonies that grew in the absence (BCR-ABL1 kinase expressed) and presence (BCR-ABL1 kinase not expressed) of tetracycline. Bone marrow cells from SCLtTA/p210BCR-ABL1/Parp1À/À Rad52À/À mice displayed the lowest BCR-ABL1-dependemt clonogenic potential compared with that from SCLtTA/p210 BCR-ABL1/Parp1À/À, SCLtTA/p210BCR-ABL1/Rad52À/À, and SCLtTA/p210BCR-ABL1 animals ( Figure 4C ).
As expected, in the absence of tetracycline, SCLtTA/ p210BCR-ABL1 animals succumbed to CML-CP-like disease in 73.7 ± 5.6 days ( Figures 4D and S4E-S4I ). Development of lethal disease in SCLtTA/p210BCR-ABL1/Parp1À/À mice (120.0 ± 8.4 days) and SCLtTA/p210BCR-ABL1/Rad52À/À mice (99.9 ± 17.6 days) was significantly prolonged in comparison with SCLtTA/p210BCR-ABL1 animals (p < 001 and p = 0.03, respectively). Importantly, mean survival time of SCLtTA/ p210BCR-ABL1/Parp1À/ÀRad52À/À mice (148.4 ± 11.7 days) was significantly prolonged in comparison with SCLtTA/ p210BCR-ABL1/Parp1À/À (p < 0.04) and SCLtTA/p210BCR-ABL1/Rad52À/À (p < 0.05) animals. Remarkably, 33% of SCLtTA/p210BCR-ABL1/Parp1À/ÀRad52À/À mice did not develop detectable leukemia during 200 days of observation, which demonstrates the ability of dual PARP1 and RAD52 inhibition to actually prevent onset of the disease.
To test the anti-tumor effect of PARPi+RAD52i against disseminated tumor, previously selected BRCA-deficient AML patient cells were injected into immunodeficient NGS mice (Cramer-Morales et al., 2013; Nieborowska-Skorska et al., 2017) . Upon engraftment, the mice were treated with PARPi talazoparib, RAD52i F79 aptamer, or talazoparib + F79 aptamer for 7 consecutive days. Talazoparib was applied in vivo because it demonstrated better pharmacokinetic properties than olaparib in rodents (Shen et al., 2013) . F79 aptamer was used because Dopa may cause severe neurobehavioral and other side effects (Eskow Jaunarajs et al., 2010) .
Although mice treated with talazoparib and F79 aptamer individually had diminished percentages of hCD45+ leukemia cells in peripheral blood, the combination of talazoparib and F79 aptamer caused an additional 2.6-to 3.8-fold reduction in the number of leukemia cells ( Figure 5A ). Untreated mice succumbed to leukemia after 37.3 ± 2.9 days, whereas those treated with F79 aptamer or talazoparib survived for 57.2 ± 3.5 days (p < 0.002) and 70.3 ± 2.5 days (p < 0.001), respectively ( Figure 5B ). Combinatorial treatment of talazoparib + F79 aptamer prolonged survival of leukemic mice to 116.7 ± 9.1 days (p < 0.001 compared with individual treatment).
In addition, we tested the effect of PARPi talazoparib combined with RAD52i D-I03 against BRCA1-deficient MDA-MB-436 and BRCA1-proficient MDA-MB-436+BRCA1 carcinoma in nu/nu mice. Pharmacokinetic and toxicity studies indicated that maximal tolerated dose of D-I03 is R50 mg/kg, and t 1/2 was 23.4 ± 17.4 hr, resulting in >1 mM maximal concentration in peripheral blood. Mice bearing subcutaneous tumors were treated with talazoparib, D-I03, or talazoparib + D-I03 for 7 consecutive days. PARPi and RAD52i when used individually Table S1 .
reduced BRCA1-deficient MDA-MB-436 tumor growth in comparison with control vehicle-treated animals, whereas the combination of these compounds exerted stronger effect ( Figure 5C ). Talazoparib + D-I03 did not affect the growth of BRCA1-proficient tumors ( Figure 5D ) and did not exert any significant toxicity against normal tissues and organs ( Figure S5 ; Table S1 ).
In conclusion, simultaneous genetic and pharmacological inhibition of PARP1 and RAD52 exerted stronger effect against BRCA-deficient tumors in vivo compared with individual inhibitors targeting PARP1 or RAD52. Single-cell RNA-sequencing (RNA-seq) analyses of untreated tumors revealed clonal heterogeneity in expression of DSB repair genes in tumor initiating cells and progenitor cells populations ( Figure S6 ), suggesting that PARPi-resistant clones may be already present at diagnosis. However, at least some of these clones should be sensitive to the inhibitors such as RAD52i, which targets unrelated DSB repair pathway. In concordance, olaparib-resistant BRCA1-mutated/53BP1-deficient SUM149PT breast carcinoma cells, olaparib-resistant BRCA1-mutated MDA-MB-436 breast carcinoma cells, and talazoparib-resistant RAD54À/À Nalm6 leukemia cells were sensitive to RAD52i Dopa ( Figure S7 ).
DISCUSSION
Patients with BRCA-deficient tumors who initially respond to PARPi often develop resistance, leading to cancer relapse . In addition, PARPi increase the probability of accumulation of additional chromosomal translocations in BRCA-deficient cells (Bunting et al., 2010) , which may facilitate disease progression. Altogether, because PARPis have become widely used to treat BRCA pathway-deficient tumors, there is an urgent need to develop novel strategies to prevent development of drug resistance, for example by killing tumor cells more rapidly and robustly before resistance mechanisms are selected for.
PARPi-mediated synthetic lethality in BRCA pathway-deficient cells is associated with increased number of lethal DSBs (Bryant et al., 2005; Farmer et al., 2005) . In BRCA-deficient cells, some of these DSBs can still be repaired by the alternative RAD52-HR and/or by RAD52-SSA (Liu and Heyer, 2011; Stark et al., 2004) potentially weakening the synthetic lethal effect of PARPi. In concordance, we detected RAD52-HR and SSA activities in PARPi-treated BRCA-deficient cells. The contribution of each mechanism may depend on the magnitude of DNA damage and capability of specific mutations in BRCA1/2 and/or in other genes (e.g., 53BP1) to engage RAD52 and/or RAD51. Moreover, the role of RAD52 in protecting cells from the toxicity of excessive DSBs is supported by recent reports demonstrating that RAD52 plays a vital role in break-induced replication and in transcript-RNA-templated DNA recombination and repair and that RAD52 acetylation is required for sustained RAD51 colocalization at DSBs (Keskin et al., 2014; Sotiriou et al., 2016; Yasuda et al., 2018) .
We and others have shown that inhibition of RAD52 DNA binding activity exerted synthetic lethality in BRCA-deficient carcinomas and leukemia cells without affecting normal cells and tissues (Cramer-Morales et al., 2013; Feng et al., 2011). Therefore, RAD52 has proved to be an important target for therapeutic intervention in BRCA-deficient tumors.
In concordance, using three different approaches (inhibitors, dominant-negative mutants, and gene knockouts) we demonstrated that simultaneous targeting of PARP1 and RAD52 exerted synergistic effect (dual synthetic lethality) against a variety of BRCA-deficient solid tumor cells and leukemia cells. At the same time, BRCA-proficient tumor cells and normal cells and tissues were not significantly affected by the combinatorial treatment.
PARPi resistance is a common phenomenon (Sonnenblick et al., 2015) , and PARPi+RAD52i-mediated dual synthetic lethality is an aggressive approach, which may lead to more effective elimination of BRCA-deficient malignant cells, thus limiting or preventing time-dependent emergence of preexisting and/or drug-induced resistant clones. In concordance, our data indicate that inhibition of RAD52 will improve therapeutic outcome of BRCA-deficient malignancies treated with PARPi while causing minimal toxicity to normal cells and tissues.
EXPERIMENTAL PROCEDURES
Further details about experimental procedures used in this work can be found in Supplemental Experimental Procedures. Nieborowska-Skorska et al., 2017) . Samples of normal hematopoietic cells were purchased from Cambrex Bio Science. Lin À
Primary Cells
CD34
+ cells were obtained from mononuclear fractions by magnetic sorting using the EasySep negative selection human progenitor cell enrichment cocktail followed by human CD34-positive selection cocktail (StemCell Technologies) as described previously (Nieborowska-Skorska et al., 2017) . Mice were provided with drinking water supplemented with 0.5 g/L tetracycline hydrochloride (Sigma-Aldrich), and leukemia was induced in 10-to 12-week-old male and female mice by withdrawal of tetracycline. CML-CP-like leukemia was characterized by splenomegaly and leukocytosis associated with expansion of mature myeloid cells as described previously (Bolton-Gillespie et al., 2013; Koschmieder et al., 2005) . Cell count and viability were determined by trypan blue exclusion. Clonogenic activity was assessed 7 days after plating of treated cells. Cell death and g-H2AX staining were examined by flow cytometry after staining with Fixable Viability Dye eFluor 780 (eBioscience) and Alexa Fluor 647 anti-g-H2AX (BD Biosciences) as described previously (Maifrede et al., 2017b) . For long-term experiments, fresh inhibitors were added every 3-4 days, and cells were expanded in fresh medium every 7 days.
In Vitro Treatment
Clonogenic Assay
Freshly harvested Lin À murine bone marrow cells were plated in serum-free MethoCult-SF H4236 (StemCell Technologies) supplemented with TET System Approved Fetal Bovine Serum (Takara Bio USA) with and without 10 mg/mL tetracycline hydrochloride in the presence of a threshold concentrations (0.1 U/mL) of recombinant murine IL-3, IL-6, and SCF. Colonies were scored after 5-7 days. BRCA1-deficient and BRCA1-proficient counterpart MDA-MB-436 cells, cultured in RPMI + 10% fetal bovine serum (FBS), were seeded on day 0 in triplicate at 5,000 cells/well. On day 1, the cells were treated with 0, 10, 20, and 50 nM olaparib in the absence or presence of 1 mM D-I03. On day 3, the treatment was repeated with media refreshment. Cells were counted on day 4 using trypan blue exclusion and were immediately plated at a density of 500 cells/well in a six-well plate, in RPMI + 10% FBS. After 2 weeks, cell survival was determined using the clonogenic assay. For this purpose, the colonies were fixed and stained with 0.05% of 10 mg/mL ethidium bromide in 50% ethanol and visualized using an Alphaimager 3400 gel documentation system.
In Vivo Treatment NSG mice (10-to 12-week-old males and females) were total-body irradiated (250 cGy) and inoculated intravenously (i. 
Statistical Analysis
Data are expressed as mean ± SD and were compared using the unpaired Student's t test; p values less than 0.05 were considered to indicate statistical significance. Mean survival time of the mice ± SE was calculated using Kaplan-Meier log-rank survival analysis. The response additivity approach was used to study the synergistic effects (Slinker, 1998) . This approach shows a positive drug combination effect when the observed combination effect (E AB ) is greater than the expected additive effect by the sum of the individual effects (E A + E B ). The combination index (CI) was calculated as CI = (E A + E B )/E AB . The p value for the possible synergistic effect is given by the significance of the interaction effect in a factorial ANOVA of the individual and combination effects. (Kim et al., 2015) . (C) Gene expression profiles in BCR-ABL1-positive CML stem cells (n = 477) obtained from 18 patients with chronic-phase CML at diagnosis (GSE76312) (Giustacchini et al., 2017 MxCre AML mice (GSE77847) (Meyer et al., 2016) ; yellow, macrophage/dendritic/neutrophil precursors; blue, hematopoietic stem/progenitorlike cells. Figure 5C , D). Hematological parameters were examined one day after the end of treatment. Blood was collected into heparinized syringes by cardiac puncture. Peripheral blood parameters (WBC = white blood cells, NE = neutrophils, LY = lymphocytes, MO = monocytes, EO = eosinophils, BA = basophils, RBC = red blood cells, HB = hemoglobin, HCT = hematocrit, MCV = mean red blood cell volume, MCH = mean corpuscular hemoglobin, PLT = platelets) were tested using Hemavet 950FS (Drew) as described before (Nieborowska-Skorska et al., 2017a 
Study Approval
Supplemental Experimental Procedures
Cell lines
The triple-negative breast cancer cell line MDA-MB-436 contains Brca1 5396 + 1G>A mutation in the splice donor site of exon 20 that results in a BRCT domain-truncated protein, and MDA-MB-436 cells ectopically express wild-type BRCA1 (MDA-MB-436 BRCA1+). SUM149PT breast cancer cells carrying Brca1 2288detT mutation and the loss of other allele were transfected with pLKO.1 lentiviral vector (Dharmacon) carrying 53BP1 shRNA (AAACCAGTAAGACCAAGTATC) or scrambled. Clones with knocked down 53BP1 (shRNA) or expressing endogenous 53BP1 protein (scrambled) were selected in puromycin followed by Western blot analysis with anti-53BP1 antibody (Abcam, ab21083) and anti-lamin B (Santa Cruz) as a loading control. Capan1, a pancreatic carcinoma cell line with truncated Brca2 (Brca2Δ/-) as well as Capan1 cells in which BRCA2 expression has been restored (Capan1 BRCA2+) were obtained from Dr. Simon Powell (Feng et al., 2011) . Human ovarian carcinoma cell line UWB1.289 carrying a germ-line BRCA1 mutation within exon 11 (2594delC) and a deletion of the wild-type allele (Brca1-null), and UWB1.289 cells with restored BRCA1 expression (UWB1.289 BRCA1+) were described before and purchased from ATCC (DelloRusso et al., 2007) . Breast cancer cell line, HCC1937, (5382insC germ-line mutation generating the truncated protein and no wild-type allele, Brca1-null) and cells with restored BRCA1 expression (BRCA1+) were obtained from Dr Ralph Scully (Scully et al., 1999) . EUFA423 cells are derived from a Fanconi anemia patient with biallelic mutations (7691 insAT and 9900 insA) in Brca2 that result in two different truncated forms of Brca2, and EUFA423 cells with restored BRCA2 expression were obtained from Dr Simon Powell (Feng et al., 2011) . Brca1-/-(clone 17) and Brca1+/+ (clone 92B) murine embryonic (ES) cells and Brca2-/-VC8 and Brca2+/+ V79 hamster cell lines carrying DR-GFP reporter cassette, and Brca2+/+ (clone 40b) and Brca2-/-(clone 42E) mouse ES cell lines carrying SA-GFP reporter cassette were obtained from Drs. Maria Jasin and Jeremy Stark (Moynahan et al., 2001; Saeki et al., 2006; Stark et al., 2004) . Nalm-6 parental cells and RAD54-/-isogenic cells were purchased from Horizon (Cambridge, UK). Burkitt lymphoma-derived Epstein-Barr virus (EBV)-positive B-cell lines Mutu and Raji and EBVimmortalized lymphoblastoid cell lines (LCLs) from healthy donors were described before (Maifrede et al., 2017) . Mice genotyping DNA isolation and purification from mice tails were performed using the REDExtract-N-Amp Tissue PCR Kit (SigmaAldrich). Genotyping for the SCLtTA and p210BCR-ABL1 transgenes and Parp1 was performed using transgene/knockoutspecific primers (Operon) and 2X GoTaq polymerase Master Mix (Promega). BCR-ABL1-specific primers (forward: 5′-GAGCGTGCAGAGTGGAGGGAGAACA-3′; reverse: 5′-GGTACCAGGAGTGTTTCTCCAGACTG-3′) amplified a 500 bp fragment using amplification conditions of 40 cycles at 94 °C for 45 seconds, 55 °C for 1 min, and 72 °C for 1 min. SCLtTA-specific primers (tTA: 5′-TTTCGATCTGGACATGTTGG-3′; SCL: 5′-AGAACAGAATTCAGGGTCTTCCTT-3′) yielded a 750 bp product using amplification conditions consisting of 40 cycles at 94°C for 40 s, 60.5 °C for 1 min, and 72 °C for 1 min. Parp1 specific primers: forward: 5'-CATGTTCGATGGGAAAGTCCC-'3; wild type reverse: 5'-CCAGCGCAGCTCAGAGAAGCCA-'3; mutant reverse: 5'-CATGTTCGATGGGAAAGTCCC-'3. The primers amplified a 112 bp fragment if wild type, a 350 bp fragment if Parp1 null, and both 112 and 350 bp fragments if heterozygous using amplification conditions consisting of 35 cycles at 94 o C for 1 min, 60 o C for 1 min, and 72 o C for 3 min. The Rad52-specific primers were: forward: 5'-AGCCAGTATACAGCGGATG-'3; wild type reverse: 5'-CAACTAGATACATGCCCACG-'3; mutant reverse: 5'-CGCATCGCCTTCTATCGCCT-'3. The amplification conditions consist of 35 cycles at 93 o C for 1 min, 55 o C for 1 min, and 72 o C for 3 min. PCR products (120 bp fragment if wild type, a 320 bp product if Rad52 null, and both 120 and 320 bp fragments if heterozygous for Rad52) were run in a 1.5% agarose gel containing ethidium bromide, and visualized using the Gel Doc TM XR+ Molecular Imager ® System (Bio-Rad).
Transfections
All transfections were performed using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA) according to manufacturer's instructions. MDA-MB-436 and EUFA423 cells and their BRCA1 and BRCA2 reconstituted counterparts were transfected with pLSXP-GFP-RAD52wt, pLSXP-YFP-RAD52(F79A), pMIG-mCherry-PARP1wt and pMIG-mCherry-PARP1(E988K). Double-positive cells were sorted 72 h after transfection with BD Biosciences Influx™ Sorter, cultured in 96-well plate and counted after 14 days.
Detection of DSBs
DSBs were detected by neutral comet assay and γ-H2AX immunofluorescence as described before Nieborowska-Skorska et al., 2012) with modifications. Comet assays were performed using the Oxiselect Comet Assay Kit (Cell Biolabs) according to the manufacturer's instructions. Images were acquired by an inverted Olympus IX70 fluorescence microscope using a FITC filter, and the percentage of tail DNA of individual cells was calculated using the OpenComet plugin of ImageJ. HR and SSA assay BRCA2-/-VC8 and BRCA2+/+ V79 hamster cell lines and BRCA1-/-(clone 17) and BRCA1+/+ (clone 92B) mES cells carrying DR-GFP reporter cassette, and BRCA2+/+ (clone 40b) and BRCA2-/-(clone 42E) mouse ES cell lines carrying SA-GFP reporter cassette were co-transfected with pCBASce1 (encoding I-Sce1) and pDsRed (transfection efficiency control) plasmids using Lipofectamine 2000 (Invitrogen) for 12 hours as described before (Nieborowska-Skorska et al., 2017b) .
